Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

"Omics" of HER2-positive breast cancer.

Bravatà V, Cammarata FP, Forte GI, Minafra L.

OMICS. 2013 Mar;17(3):119-29. doi: 10.1089/omi.2012.0099. Epub 2013 Feb 19. Review.

PMID:
23421906
2.

Breast cancer as an acquired thrombophilic state.

Kyriazi V.

J Breast Cancer. 2012 Jun;15(2):148-56. doi: 10.4048/jbc.2012.15.2.148. Epub 2012 Jun 28.

3.

Unmasking epithelial-mesenchymal transition in a breast cancer primary culture: a study report.

Minafra L, Norata R, Bravatà V, Viola M, Lupo C, Gelfi C, Messa C.

BMC Res Notes. 2012 Jul 3;5:343. doi: 10.1186/1756-0500-5-343.

4.

MTHFR polymorphisms and breast cancer risk.

Hosseini M, Houshmand M, Ebrahimi A.

Arch Med Sci. 2011 Feb;7(1):134-7. doi: 10.5114/aoms.2011.20618. Epub 2011 Mar 8.

5.

Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.

Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY.

Clin Nucl Med. 2012 Feb;37(2):121-7. doi: 10.1097/RLU.0b013e3182393599.

PMID:
22228332
6.

Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma.

Amann T, Kirovski G, Bosserhoff AK, Hellerbrand C.

Mol Membr Biol. 2011 Apr;28(3):182-6. doi: 10.3109/09687688.2011.554447. Epub 2011 Feb 18.

PMID:
21332301
7.

The XbaI G>T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer.

Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA, Antoch G, Bockisch A, Kimmig R, Schmid KW, Stahl AR.

J Nucl Med. 2010 Aug;51(8):1191-7. doi: 10.2967/jnumed.110.075721.

9.

Imaging and 'omic' methods for the molecular diagnosis of cancer.

Bohndiek SE, Brindle KM.

Expert Rev Mol Diagn. 2010 May;10(4):417-34. doi: 10.1586/erm.10.20. Review.

PMID:
20465497
10.

Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction.

Lorenzen S, Panzram B, Keller G, Lordick F, Herrmann K, Becker K, Langer R, Schwaiger M, Siewert JR, Ott K.

Mol Imaging Biol. 2011 Feb;13(1):178-86. doi: 10.1007/s11307-010-0330-0.

PMID:
20449668
11.

Partial volume correction strategies for quantitative FDG PET in oncology.

Hoetjes NJ, van Velden FH, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, Boellaard R.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1679-87. doi: 10.1007/s00259-010-1472-7. Epub 2010 Apr 27.

12.

Putative molecular signatures for the imaging of prostate cancer.

Yang S Y, Adelstein J, Kassis AI.

Expert Rev Mol Diagn. 2010 Jan;10(1):65-74. doi: 10.1586/erm.09.73. Review.

PMID:
20014923
13.

Breast cancer single-nucleotide polymorphisms: statistical significance and clinical utility.

Offit K.

J Natl Cancer Inst. 2009 Jul 15;101(14):973-5. doi: 10.1093/jnci/djp184. Epub 2009 Jun 30. No abstract available.

PMID:
19567420
14.

Common genetic variation and human traits.

Goldstein DB.

N Engl J Med. 2009 Apr 23;360(17):1696-8. doi: 10.1056/NEJMp0806284. Epub 2009 Apr 15. No abstract available.

PMID:
19369660
15.

Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.

Chang-Claude J, Ambrosone CB, Lilla C, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Popanda O.

Br J Cancer. 2009 May 19;100(10):1680-6. doi: 10.1038/sj.bjc.6605036. Epub 2009 Apr 14.

16.

A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).

Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, Peplonska B, Brinton LA, Sigurdson A, Doody M, Bhatti P, Alexander BH, Buring J, Lee IM, Vatten LJ, Hveem K, Kumle M, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Chanock SJ, Hunter DJ.

Nat Genet. 2009 May;41(5):579-84. doi: 10.1038/ng.353. Epub 2009 Mar 29.

17.

18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.

Hamada K, Tomita Y, Qiu Y, Zhang B, Ueda T, Myoui A, Higuchi I, Yoshikawa H, Aozasa K, Hatazawa J.

Ann Nucl Med. 2008 Oct;22(8):699-705. doi: 10.1007/s12149-008-0173-9. Epub 2008 Nov 4.

PMID:
18982473
18.

PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response.

Heron DE, Andrade RS, Beriwal S, Smith RP.

Am J Clin Oncol. 2008 Aug;31(4):352-62. doi: 10.1097/COC.0b013e318162f150. Review.

PMID:
18845994
19.

The serotonin transporter genotype is associated with intermediate brain phenotypes that depend on the context of eliciting stressor.

Kalin NH, Shelton SE, Fox AS, Rogers J, Oakes TR, Davidson RJ.

Mol Psychiatry. 2008 Nov;13(11):1021-7. doi: 10.1038/mp.2008.37. Epub 2008 Apr 15.

20.

Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells.

Martin CM, Ferdous A, Gallardo T, Humphries C, Sadek H, Caprioli A, Garcia JA, Szweda LI, Garry MG, Garry DJ.

Circ Res. 2008 May 9;102(9):1075-81. doi: 10.1161/CIRCRESAHA.107.161729. Epub 2008 Mar 20.

Supplemental Content

Support Center